Prime Medicine (PRME) Assets Average (2022 - 2026)
Prime Medicine's (PRME) quarterly Assets Average came in at $318.7 million in Q1 2026, up 1.88% YoY from $312.8 million in Q1 2025, and down 12.41% on a QoQ basis from $363.9 million in Q4 2025.
Prime Medicine (PRME) Assets Average (2022 - 2026) Analysis & Trends
Prime Medicine (PRME) has 5 years of Assets Average data on file, last reported at $318.7 million in Q1 2026.
- Quarterly Assets Average rose 1.88% year-over-year to $318.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $318.7 million (up 1.88% YoY) and the FY2025 annual result came in at $320.1 million, up 30.3% from the prior year.
- Assets Average eased to $318.7 million in Q1 2026, from $363.9 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $363.9 million in Q4 2025 to a low of $216.5 million in Q4 2023.
- A 5-year average of $298.7 million and a median of $301.2 million in 2023 frame the typical range for Assets Average.
- The widest YoY moves for Assets Average: up 45.57% in 2024, down 25.4% in 2024.
- Tracing PRME's Assets Average over 5 years: stood at $287.8 million in 2022, then slipped by 24.77% to $216.5 million in 2023, then soared by 45.57% to $315.1 million in 2024, then grew by 15.46% to $363.9 million in 2025, then retreated by 12.41% to $318.7 million in 2026.
- The last three Assets Average figures came in at $318.7 million (Q1 2026), $363.9 million (Q4 2025), and $332.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Prime Medicine | 558.48 Mn | 558.48 Mn | - | 271.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 271.89 Mn |
| Mar 31, 2026 | 318.73 Mn |
| Dec 31, 2025 | 363.87 Mn |
| Sep 30, 2025 | 332.01 Mn |
| Jun 30, 2025 | 303.59 Mn |
| Mar 31, 2025 | 312.84 Mn |
| Dec 31, 2024 | 315.15 Mn |
| Sep 30, 2024 | 296.24 Mn |
| Jun 30, 2024 | 285.54 Mn |
| Mar 31, 2024 | 252.62 Mn |
| Dec 31, 2023 | 216.50 Mn |
| Sep 30, 2023 | 260.01 Mn |
| Jun 30, 2023 | 298.91 Mn |
| Mar 31, 2023 | 338.63 Mn |
| Dec 31, 2022 | 287.79 Mn |